- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
eAPPENDIX 2. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR DRUGS AND MAXIMUM DOSE LEVELS
eAPPENDIX 2. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR DRUGS AND MAXIMUM DOSE LEVELS
Evaluated renin-angiotensin-aldosterone system (RAAS) inhibitor drugs and their maximum doses, listed in descending order of observed frequency at index: lisinopril, 40 mg; losartan, 100 mg; valsartan, 320 mg; benazepril, 80 mg; olmesartan, 40 mg; enalapril, 40 mg; spironolactone, 200 mg; irbesartan, 300 mg; ramipril, 10 mg; quinapril, 80 mg; telmisartan, 80 mg; candesartan, 32 mg; captopril, 450 mg; fosinopril, 40 mg; trandolapril, 8 mg; moexipril, 30 mg; aliskiren, 300 mg; eplerenone, 100 mg; perindopril, 8 mg; eprosartan, 800 mg; azilsartan, 80 mg.
Aliskiren/valsartan formulated 150 mg-160 mg (a partial dose of each of 2 RAAS inhibitor drugs) was considered a partial dose (submaximum).
